Elizabeth Fox

MedicineBiochemistry, Genetics and Molecular BiologyComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.257Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071

Top 59%

0.257DataRank

Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

Papers

Driven by 30 papers — median percentile 41. Top paper: “Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial”.

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30023-1

N/A

5.0DataRank · unranked

337 citations

Elizabeth Fox, Melinda S. Merchant, Joel M. Reid, Rachel A. Kudgus, Xiaowei Liu +6 more

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group

Cancer Discovery(2024)10.1158/2159-8290.cd-23-1376

N/A

0.590DataRank · unranked

16 citations

Alex G. Lee, Steven P. Angus, Christopher Davis, Donald A. Barkauskas, David Hall +10 more

Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3009

N/A

0.518DataRank · unranked

16 citations

Amit J. Sabnis, Paul M. Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

The Journal of Clinical Pharmacology(2021)10.1002/jcph.1958

N/A

0.469DataRank · unranked

8 citations

Diane R. Mould, Ying Yuan, Elizabeth Fox, Emily Greengard, Douglas V. Faller +2 more

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors

Pediatric Blood & Cancer(2021)10.1002/pbc.29282

N/A

0.461DataRank · unranked

10 citations

Brigitte C. Widemann, Pamela S. Hinds, Rochelle Bagatell, Suzanne Shusterman, Emily Stern +12 more

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071

Top 59%

0.257DataRank

Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10008

N/A

0DataRank · unranked

2 citations

Olive S. Eckstein, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10018

N/A

0DataRank · unranked

0 citations

Xiaowei Liu, Charles G. Minard, Sarah Menig, Joel M. Reid, Emasenyie Isikwei +6 more

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2164

N/A

0DataRank · unranked

72 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Transgenic Drosophila lines for LexA-dependent gene and growth regulation

G3 Genes Genomes Genetics(2022)10.1093/g3journal/jkac018

N/A

0DataRank · unranked

21 citations

Deborah D. Tsao, Celine Bennett, Elaine Wang, Jax Floyd, Ashley Tay +13 more

Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study

Neuro-Oncology Advances(2022)10.1093/noajnl/vdac073

N/A

0DataRank · unranked

16 citations

Tabitha Cooney, Xiaodong Yang, Sharmistha Pal, Ralph P. Ermoian, Amar Gajjar +9 more

Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10009

N/A

0DataRank · unranked

21 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad085

N/A

0DataRank · unranked

95 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma

Cancer(2023)10.1002/cncr.34786

N/A

0DataRank · unranked

32 citations

Heba Ijaz, Lea F. Surrey, Mariarita Santi, Xiaowei Liu, Charles G. Minard +6 more

Simplified homology-assisted CRISPR for gene editing in Drosophila

G3 Genes Genomes Genetics(2023)10.1093/g3journal/jkad277

N/A

0DataRank · unranked

4 citations

Elizabeth Fox, Townley Chisholm, Nicole Lantz, Arjun Rajan, William D. Phillips +19 more

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712

Pediatric Blood & Cancer(2023)10.1002/pbc.30672

N/A

0DataRank · unranked

3 citations

Xiaowei Liu, Charles G. Minard, Emasenyie Isikwei, Joel M. Reid, Terzah M. Horton +4 more

Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10007

N/A

0DataRank · unranked

20 citations

Alexander J. Chou, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A children’s oncology group pediatric early-phase clinical Trial Network study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11527

N/A

0DataRank · unranked

11 citations

Katherine A. Janeway, Charles G. Minard, David Hall, Brian D. Crompton, Alexander J. Lazar +8 more

A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15131

N/A

0DataRank · unranked

9 citations

Julia Glade Bender, Charles G. Minard, Xiaowei Liu, Kristina Z. Denic, Joel M. Reid +8 more

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10008

N/A

0DataRank · unranked

5 citations

Kathleen Ludwig, David Hall, Donald A. Barkauskas, Stephan D. Voss, Steven G. DuBois +12 more

Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10006

N/A

0DataRank · unranked

4 citations

Rajen Mody, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo +14 more

CRISPR/Cas9 gene editing to generate Drosophila LexA lines in secondary school classes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.06.22.546134

N/A

0DataRank · unranked

1 citations

Elizabeth Fox, Townley Chisholm, Nicole Lantz, Arjun Rajan, William D. Phillips +19 more

Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

(2023)10.1158/1078-0432.c.6532749

N/A

0DataRank · unranked

0 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

(2023)10.1158/1078-0432.c.6532749.v1

N/A

0DataRank · unranked

0 citations

Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard +5 more

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)

European Journal of Cancer(2024)10.1016/j.ejca.2024.114241

N/A

0DataRank · unranked

15 citations

Joel M. Reid, Charles G. Minard, Sarah E. Woodfield, Kristina Z. Denic, Emasenyie Isikwei +7 more

A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase‐Clinical Trial Network (PEP‐CTN)

Pediatric Blood & Cancer(2021)10.1002/pbc.28892

N/A

0DataRank · unranked

38 citations

Bill H. Chang, Joel M. Reid, Xiaowei Liu, Charles G. Minard, Jane B. Trepel +4 more

A phase II study of larotrectinib for children with newly diagnosed solid tumors and relapsed acute leukemias harboring TRK fusions: Children’s Oncology Group study ADVL1823.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10560

N/A

0DataRank · unranked

2 citations

Kathleen Ludwig, Donald A. Barkauskas, Steven G. DuBois, Joan Ronan, Erin R. Rudzinski +10 more

Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10010

N/A

0DataRank · unranked

26 citations

Brigitte C. Widemann, Donald A. Barkauskas, David Hall, Joel M. Reid, Stephan D. Voss +4 more

Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10019

N/A

0DataRank · unranked

3 citations

Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg +4 more

Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10007

N/A

0DataRank · unranked

3 citations

Katherine A. Janeway, David R. Patton, Jennifer Lee, Brent Coffey, P. Mickey Williams +16 more

Elizabeth Fox

Indexed papers

Top data-sharing exemplar

Papers